moxifloxacin has been researched along with arachidonic acid in 1 studies
| Studies (moxifloxacin) | Trials (moxifloxacin) | Recent Studies (post-2010) (moxifloxacin) | Studies (arachidonic acid) | Trials (arachidonic acid) | Recent Studies (post-2010) (arachidonic acid) |
|---|---|---|---|---|---|
| 3,157 | 552 | 1,690 | 19,295 | 486 | 3,040 |
| Protein | Taxonomy | moxifloxacin (IC50) | arachidonic acid (IC50) |
|---|---|---|---|
| 60 kDa heat shock protein, mitochondrial | Homo sapiens (human) | 4.5 | |
| Fatty acid-binding protein, adipocyte | Homo sapiens (human) | 2.75 | |
| 10 kDa heat shock protein, mitochondrial | Homo sapiens (human) | 4.5 | |
| 60 kDa chaperonin | Escherichia coli | 7.3 | |
| 10 kDa chaperonin | Escherichia coli | 7.3 | |
| Solute carrier organic anion transporter family member 1B3 | Homo sapiens (human) | 1.0715 | |
| Solute carrier organic anion transporter family member 1B1 | Homo sapiens (human) | 0.6026 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Fijorek, K; Glinka, A; Mendyk, A; Polak, S; Wiśniowska, B | 1 |
1 other study(ies) available for moxifloxacin and arachidonic acid
| Article | Year |
|---|---|
Predictive model for L-type channel inhibition: multichannel block in QT prolongation risk assessment.
Topics: Artificial Intelligence; Calcium Channel Blockers; Calcium Channels, L-Type; Cell Line; Computational Biology; Computer Simulation; Drugs, Investigational; Ether-A-Go-Go Potassium Channels; Expert Systems; Heart Rate; Humans; Models, Biological; Myocytes, Cardiac; NAV1.5 Voltage-Gated Sodium Channel; Potassium Channel Blockers; Quantitative Structure-Activity Relationship; Risk Assessment; Shaker Superfamily of Potassium Channels; Torsades de Pointes; Voltage-Gated Sodium Channel Blockers | 2012 |